Presentations 2003
10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003
1. Exposure to HAART is associated with an increased risk of myocardial infarction: The DAD study. N Friis-Møller, R Weber, A D´Arminio Monforte, W El-Sadr, P Reiss, F Dabis, L Morfeldt, S De Wit, C Pradier, G Calvo, M Law, O Kirk, C Sabin, JD Lundgren. (DAD 130)
2. Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure: The PLATO collaboration. B Ledergerber, JD Lundgren, G Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Armenio Monforte, C Mussioni, F Lampe, MJ Gill, A Phillips.
(PLATO 146lb)
3. Changes in AIDS, death Rates and survival after AIDS in the EuroSIDA study: 1994-2002. A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, A D´Arminio-Monforte, B Knysz, M Dietrich, AN Phillips, JD Lundgren.
(EuroSIDA 180)
4. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response. JAC. Sterne, M May, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, J Lundgren, JS Fusco, S Staszewski, F Raffi, RS Hogg, AN Phillips, MJ Gill, G Faetkenheuer, G Chene.
(Art Cohort 181)
5. The changing incidence of clinical AIDS events in 12,574 treatment-naïve patients starting HAART. C Sabin, A D´Arminio Monforte, M May, S Grabar, P Reiss, J Lundgren, A Justice, S Staszewski, C Leport, F Dabis, JSG Montaner, M Johnson, J Gill, G Faetkenheuer, M Egger.
(Art Cohort 569)
British HIV Association Conference, Manchester, April 2003
1. ART and myocardial infarction: how to deal with the incertainty. JD Lundgren
2nd International AIDS Society Conference, Paris, July 2003
1. Factors contributing to the success of ART following three class virological failure: The PLATO collaboration.B Ledergerber, JD Lundgren, GP Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A d´Arminio Monforte, C Mussini, F Lampe, MJ Gill and AN Phillips.
(Plato 576)
2. Presence of GB virus C and response to HAART, analysed within the MaxCmin1 trial comparing the efficacy and safety of indinavir/ritonavir versus saquinavir/ritonavir. HL Tilmann, T Kaiser, Z Fox, S Staszewski, F Antunes, A d´Arminio Monforte, A Telenti, UB Dragsted and JD Lundgren on behalf of the MaxCmin Trial Group.
(MaxCmin 1006)
3. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted and JD Lundgren for the MaxCmin2 Trial Group.
(MaxCmin2 LB23)
5th International Conference on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 2003.
1. Safety on NNRTI therapy. Data from the EuroSIDA study. N Friis-Møller, O Kirk, P Reiss, A Mocroft, C Katlama, A Horban, D Banhegyi, J Gatell, B Clotet, AN Phillips and JD Lundgren for the EuroSIDA Study Group.
(EuroSIDA 24)
2. Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomised, open-label and multi centre trial in adult HIV-1 infection: MaxCmin1 trial. JD Lundgren, A Hill, Z Fox, N Clumeck, JN Bruun, J Bennetucci, I Cassetti, P Vernazza, A Rieger and UB Dragsted on behalf of the MaxCmin1 trial.
(MaxCmin1 126)
43nd ICAAC, Chicago, September 2003
1. Risk of death following triple class virological failure: The PLATO Collaboration. JD Lundgren, B Ledergerber, GP Fusco, R Weber, P Reiss, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Arminio Monforte, C Mussini, F Lampe, MJ Gill, AN Phillips.
9th EACS, Warsaw, October 2003
1. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. U Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, A Duran, B Peters, N Obel, A Castagna, U Dragsted, J Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin 1 F2/5)
2. Virologic outcome of patients with virologic failure who start a regimen containing Abacavir: EuroSIDA Study. C Cabrera, A Cozzi-Lepri, AN Phillips, C Loveday, T Puig, O Kirk, M Ait-Khaled, B Ledergerber, J Lundgren, B Clotet, L Ruiz.
(EuroSIDA F6/5)
3. Prevalence of lipodystrophy and retinoid syndrome in a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. S De Wit, H Wand, M Law, A Castagna, JN Bruun, M Youle, P Vernazza, I Cassetti, J Benetucci, U Dragsted, JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin 1 F8/2)
4. Hepatitis B (HBV) in the EuroSIDA Cohort: prevalence and impact on mortality, AIDS progression and response to HAART. D Konopnicki, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, O Kirk, S Vella, A Mocroft and JD Lundgren for the EuroSIDA Group.
(EuroSIDA F9/3)
5. Changing incidence of central nervous system (CNS) AIDS-related diseases in the EuroSIDA cohort. A d'Arminio Monforte, P Cinque, A Mocroft, FD Goebel, F Antunes, C Katlama, US Justesen, S Vella, O Kirk, JD Lundgren for the EuroSida Study Group.
(EuroSIDA F9/6)
6. Changes in hospital admissions across Europe in 1995-2002. A D’Arminio Monforte, A Mocroft, O Kirk, MA Johnson, N Friis-Moller, D Banhegyi, A Blaxhult, F Mulcahy, JM Gatell, JD Lundgren for the EuroSIDA study group.
(EuroSIDA F9/7)
7. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted, JD Lundgren for the MaxCmin2 trial group.
(MaxCmin2 F11/3)
8. Influence of Hepatitis C coinfection on HIV disease progression within the EuroSIDA Cohort. J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, P Reiss, L Machala, O Kirk, B Ledergerber, JD Lundgren for the EuroSIDA study group.
(EuroSIDA F12/4)
9. Regional differences in characteristics of HIV-patients from across Europe The EuroSIDA study. LViksna, A Mocroft, B Knysz, JP Viard, M Dietrich, D Duiculescu, A Blaxhult, F Antunes, JD Lundgren, O Kirk for the EuroSIDA Study Group.
(EuroSIDA 18.2/2)
10. Use of and response to antiretroviral therapy in regions of Europe The EuroSIDA Study. A Horban, A Mocroft, B Ledergerber, A Johnson, S Chaplinskas, JM Gatell, A Chiesi, AN Phillips, JD Lundgren, O Kirk for the EuroSIDA study group.
(EuroSIDA 18.2/3)
Updated: 13 Dec 2005